Substance use disorder a bio-directional subset of reward deficiency syndrome

Kenneth Blum, Mark Gold, Z. Demetrovics, Trevor Archer, Panayotis K. Thanos, David Baron, Rajendra D. Badgaiyan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This commentary is to inform clinicians challenged with an increase in people seeking treatment for Substance Use Disorder (SUD), that the ninety percent revolving door, is, in part, due to post-withdrawal, untreated neurotoxicity. This impairment attenuates neurotransmitter signaling and compromises resting state functional connectivity, leading to unwanted sequelae including depression, sleep disturbances, sensation seeking, lack of satisfaction and impulsivity. Neuroimaging studies indicate that neurobiological recovery can take years. Like a "double edge sword" SUD has a biological bi -directional (bio-directional) effect on the brain reward circuitry. The acute intake of psychoactive drugs results in heightened dopaminergic activity, while, the opposite, hypodopaminergia occurs following chronic abuse. Individuals with SUD can have a genetic predisposition, compounded by stress and neurotoxically induced, epigenetic insults that impact recovery from protracted abstinence. Follow-up post -short-term recovery usually includes supportive therapies and programs like 12 -steps and other fellowships. However, relapse will usually occur if post -short-term recovery hypodopaminergia is not treated with attempts at epigenetic manipulation of compromised brain neurochemistry using some manner of pro-dopamine regulation.

Original languageEnglish
Pages (from-to)1534-1548
Number of pages15
JournalFrontiers in bioscience (Landmark edition)
Volume22
Publication statusPublished - Jun 1 2017

Fingerprint

Reward
Substance-Related Disorders
Epigenomics
Recovery
Neurochemistry
Brain
Impulsive Behavior
Psychotropic Drugs
Genetic Predisposition to Disease
Neuroimaging
Neurotransmitter Agents
Dopamine
Sleep
Depression
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Blum, K., Gold, M., Demetrovics, Z., Archer, T., Thanos, P. K., Baron, D., & Badgaiyan, R. D. (2017). Substance use disorder a bio-directional subset of reward deficiency syndrome. Frontiers in bioscience (Landmark edition), 22, 1534-1548.

Substance use disorder a bio-directional subset of reward deficiency syndrome. / Blum, Kenneth; Gold, Mark; Demetrovics, Z.; Archer, Trevor; Thanos, Panayotis K.; Baron, David; Badgaiyan, Rajendra D.

In: Frontiers in bioscience (Landmark edition), Vol. 22, 01.06.2017, p. 1534-1548.

Research output: Contribution to journalArticle

Blum, K, Gold, M, Demetrovics, Z, Archer, T, Thanos, PK, Baron, D & Badgaiyan, RD 2017, 'Substance use disorder a bio-directional subset of reward deficiency syndrome', Frontiers in bioscience (Landmark edition), vol. 22, pp. 1534-1548.
Blum, Kenneth ; Gold, Mark ; Demetrovics, Z. ; Archer, Trevor ; Thanos, Panayotis K. ; Baron, David ; Badgaiyan, Rajendra D. / Substance use disorder a bio-directional subset of reward deficiency syndrome. In: Frontiers in bioscience (Landmark edition). 2017 ; Vol. 22. pp. 1534-1548.
@article{ecd47bd888d14c0f9eed089dc8ba5427,
title = "Substance use disorder a bio-directional subset of reward deficiency syndrome",
abstract = "This commentary is to inform clinicians challenged with an increase in people seeking treatment for Substance Use Disorder (SUD), that the ninety percent revolving door, is, in part, due to post-withdrawal, untreated neurotoxicity. This impairment attenuates neurotransmitter signaling and compromises resting state functional connectivity, leading to unwanted sequelae including depression, sleep disturbances, sensation seeking, lack of satisfaction and impulsivity. Neuroimaging studies indicate that neurobiological recovery can take years. Like a {"}double edge sword{"} SUD has a biological bi -directional (bio-directional) effect on the brain reward circuitry. The acute intake of psychoactive drugs results in heightened dopaminergic activity, while, the opposite, hypodopaminergia occurs following chronic abuse. Individuals with SUD can have a genetic predisposition, compounded by stress and neurotoxically induced, epigenetic insults that impact recovery from protracted abstinence. Follow-up post -short-term recovery usually includes supportive therapies and programs like 12 -steps and other fellowships. However, relapse will usually occur if post -short-term recovery hypodopaminergia is not treated with attempts at epigenetic manipulation of compromised brain neurochemistry using some manner of pro-dopamine regulation.",
author = "Kenneth Blum and Mark Gold and Z. Demetrovics and Trevor Archer and Thanos, {Panayotis K.} and David Baron and Badgaiyan, {Rajendra D.}",
year = "2017",
month = "6",
day = "1",
language = "English",
volume = "22",
pages = "1534--1548",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Substance use disorder a bio-directional subset of reward deficiency syndrome

AU - Blum, Kenneth

AU - Gold, Mark

AU - Demetrovics, Z.

AU - Archer, Trevor

AU - Thanos, Panayotis K.

AU - Baron, David

AU - Badgaiyan, Rajendra D.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - This commentary is to inform clinicians challenged with an increase in people seeking treatment for Substance Use Disorder (SUD), that the ninety percent revolving door, is, in part, due to post-withdrawal, untreated neurotoxicity. This impairment attenuates neurotransmitter signaling and compromises resting state functional connectivity, leading to unwanted sequelae including depression, sleep disturbances, sensation seeking, lack of satisfaction and impulsivity. Neuroimaging studies indicate that neurobiological recovery can take years. Like a "double edge sword" SUD has a biological bi -directional (bio-directional) effect on the brain reward circuitry. The acute intake of psychoactive drugs results in heightened dopaminergic activity, while, the opposite, hypodopaminergia occurs following chronic abuse. Individuals with SUD can have a genetic predisposition, compounded by stress and neurotoxically induced, epigenetic insults that impact recovery from protracted abstinence. Follow-up post -short-term recovery usually includes supportive therapies and programs like 12 -steps and other fellowships. However, relapse will usually occur if post -short-term recovery hypodopaminergia is not treated with attempts at epigenetic manipulation of compromised brain neurochemistry using some manner of pro-dopamine regulation.

AB - This commentary is to inform clinicians challenged with an increase in people seeking treatment for Substance Use Disorder (SUD), that the ninety percent revolving door, is, in part, due to post-withdrawal, untreated neurotoxicity. This impairment attenuates neurotransmitter signaling and compromises resting state functional connectivity, leading to unwanted sequelae including depression, sleep disturbances, sensation seeking, lack of satisfaction and impulsivity. Neuroimaging studies indicate that neurobiological recovery can take years. Like a "double edge sword" SUD has a biological bi -directional (bio-directional) effect on the brain reward circuitry. The acute intake of psychoactive drugs results in heightened dopaminergic activity, while, the opposite, hypodopaminergia occurs following chronic abuse. Individuals with SUD can have a genetic predisposition, compounded by stress and neurotoxically induced, epigenetic insults that impact recovery from protracted abstinence. Follow-up post -short-term recovery usually includes supportive therapies and programs like 12 -steps and other fellowships. However, relapse will usually occur if post -short-term recovery hypodopaminergia is not treated with attempts at epigenetic manipulation of compromised brain neurochemistry using some manner of pro-dopamine regulation.

UR - http://www.scopus.com/inward/record.url?scp=85028655313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028655313&partnerID=8YFLogxK

M3 - Article

C2 - 28410131

AN - SCOPUS:85028655313

VL - 22

SP - 1534

EP - 1548

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -